Precision BioSciences Set for Breakout with Key Gene Editing Trials
AI Prediction of Precision BioSciences, Inc. (DTIL)
Precision BioSciences, a clinical stage gene editing company, is positioned for potential share price appreciation with upcoming clinical catalysts. The company's focus on gene-editing therapies for high unmet needs, specifically its PBGENE-HBV and PBGENE-DMD programs, offers significant upside potential.
Precision BioSciences is actively developing its proprietary ARCUS genome editing platform to create in vivo gene editing therapies targeting diseases with high unmet needs. Key programs include PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy. Both programs are approaching significant clinical milestones, with expected data readouts that could serve as major catalysts for the stock. The company's strategic focus on these diseases, combined with a robust clinical development pipeline and a strong cash position to support operations through 2028, positions Precision BioSciences as a compelling investment in the biotech sector. These factors are expected to significantly influence the company's stock price in the near term.
DTIL Report Information
Prediction Date2026-03-23
Close @ Prediction$6.52
Mkt Cap206m
IPO DateN/a
AI-derived Information
Recent News for DTIL
- Sep 2, 4:15 pm — Flyte Secures International Approval to Launch Private Aviation Service Across The Bahamas and Caribbean (GlobeNewswire RSS)
- Aug 28, 9:00 am — Luxshare Precision erwartet für die ersten neun Monate des Jahres 2026 einen Anstieg des Nettogewinns um 15 % bis 25 % (PRNewswire RSS)
- Aug 28, 9:00 am — Luxshare Precision prevé que su beneficio neto aumente un 15-25 % en los primeros nueve meses de 2026 (PRNewswire RSS)
- Aug 28, 9:00 am — Luxshare Precision Expects Net Profit to Rise 15%-25% in the First Nine Months of 2026 (PRNewswire RSS)
- Aug 28, 9:00 am — Luxshare Precision prévoit une hausse de son bénéfice net de 15 à 25 % au cours des neuf premiers mois de 2026 (PRNewswire RSS)
- Aug 28, 2:41 am — Luxshare Precision annonce une croissance de 40,2 % de son chiffre d'affaires au premier semestre 2026 ; la répartition de ses activités favorise l'amélioration de ses marges (PRNewswire RSS)
- Aug 27, 10:58 am — Innovation durch Zusammenarbeit macht Precision BioLogic zu einem festen Begriff in der Diagnostik und Forschung im Bereich der Hämostase (PRNewswire RSS)
- Aug 27, 9:30 am — L'innovation collaborative propulse Precision BioLogic sur le devant de la scène en diagnostic et en recherche en hémostase (PRNewswire RSS)
- Aug 27, 9:30 am — Innovation Through Collaboration Puts Precision BioLogic on the Map in Hemostasis Diagnostics and Research (PRNewswire RSS)
- Aug 27, 9:30 am — Precision BioLogic, líder en diagnóstico e investigación de la hemostasia (PRNewswire RSS)
- Aug 27, 8:44 am — Iylon Precision Oncology, LLC Appoints Dr. Mary Lopresti as Chief Medical Officer (PRNewswire RSS)
- Aug 27, 8:00 am — Catheter Precision Achieves Major Commercial Milestones with Cardinal Health, Johns Hopkins and the placement of the First VIVO System in Germany (GlobeNewswire RSS)
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.
Subscribe
Login
Please login to comment
0 Comments
Oldest